BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38556260)

  • 21. Physiologically Based Pharmacokinetic Modeling of Rosuvastatin to Predict Transporter-Mediated Drug-Drug Interactions.
    Hanke N; Gómez-Mantilla JD; Ishiguro N; Stopfer P; Nock V
    Pharm Res; 2021 Oct; 38(10):1645-1661. PubMed ID: 34664206
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting.
    Dahan A; Amidon GL
    Am J Physiol Gastrointest Liver Physiol; 2009 Aug; 297(2):G371-7. PubMed ID: 19541926
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects of human immunodeficiency virus infection on the expression of the drug efflux proteins P-glycoprotein and breast cancer resistance protein in a human intestine model.
    Ellis K; Marlin JW; Taylor TA; Fitting S; Hauser KF; Rice G; McRae M
    J Pharm Pharmacol; 2015 Feb; 67(2):178-88. PubMed ID: 25557407
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Breast cancer resistance protein BCRP (ABCG2)-mediated transepithelial nitrofurantoin secretion and its regulation in human intestinal epithelial (Caco-2) layers.
    Wright JA; Haslam IS; Coleman T; Simmons NL
    Eur J Pharmacol; 2011 Dec; 672(1-3):70-6. PubMed ID: 22004608
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular expression and functional evidence of a drug efflux pump (BCRP) in human corneal epithelial cells.
    Karla PK; Earla R; Boddu SH; Johnston TP; Pal D; Mitra A
    Curr Eye Res; 2009 Jan; 34(1):1-9. PubMed ID: 19172464
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tetrahydrocannabinol and Its Major Metabolites Are Not (or Are Poor) Substrates or Inhibitors of Human P-Glycoprotein [ATP-Binding Cassette (ABC) B1] and Breast Cancer Resistance Protein (ABCG2).
    Chen X; Unadkat JD; Mao Q
    Drug Metab Dispos; 2021 Oct; 49(10):910-918. PubMed ID: 34326138
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe.
    Urquhart BL; Ware JA; Tirona RG; Ho RH; Leake BF; Schwarz UI; Zaher H; Palandra J; Gregor JC; Dresser GK; Kim RB
    Pharmacogenet Genomics; 2008 May; 18(5):439-48. PubMed ID: 18408567
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ABCG2/BCRP: variants, transporter interaction profile of substrates and inhibitors.
    Safar Z; Kis E; Erdo F; Zolnerciks JK; Krajcsi P
    Expert Opin Drug Metab Toxicol; 2019 Apr; 15(4):313-328. PubMed ID: 30856014
    [TBL] [Abstract]